Trial Profile
A Phase 1a/1b, Multicenter, Open Label, Dosefinding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Dual Dna-pk and Tor Kinase Inhibitor, Cc-115, Administered Orally to Subjects With Advanced Solid Tumors and Hematologic Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs CC 115 (Primary)
- Indications Chronic lymphocytic leukaemia; Head and neck cancer; Multiple myeloma; Non-Hodgkin's lymphoma; Solid tumours; Squamous cell cancer; T-cell prolymphocytic leukaemia
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Celgene Corporation
- 05 May 2021 Status changed from active, no longer recruiting to completed.
- 01 Dec 2020 Planned End Date changed from 28 Dec 2020 to 28 Dec 2021.
- 25 Feb 2020 Planned End Date changed from 30 Dec 2019 to 28 Dec 2020.